Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR
Abstract
Allogeneic hematopoietic stem cell transplantation (allo‐HCT) remains the only potentially curative treatment option for relapsed follicular lymphoma (FL), yet questions remain about the optimal timing. This study analyzed long‐term outcomes and associated factors among recipients of allo‐HCT with FL.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 09, 2018
- Source ID
- 10.1002/cncr.31264
Entities
People
- Anna Sureda
- Ariane Boumedil
- Harry Schouten
- Herve Finel
- Jeanette Carreras
- Marcelo C Pasquini
- Mehdi Hamadani
- Mei‐jie Zhang
- Peter Dreger
- Silvia Montoto
- Sonali M Smith
- Stephen M. Robinson
- Timothy Fenske
Organizations
- Alexion Pharmaceuticals
- Astellas Pharma (United States)
- AstraZeneca
- Celgene
- Chiron Corporation
- Fred Hutchinson Cancer Center
- Genzyme
- Health Resources and Services Administration
- Medical College of Wisconsin
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Onyx Pharmaceuticals
- Roswell Park Comprehensive Cancer Center
- Seagen
- St Bartholomew's Hospital
- St. Baldrick's Foundation
- Takeda Oncology
- University of Chicago
- University of Minnesota